Indaptus Therapeutics Inc. (NASDAQ:INDP) Stock Jumps As FDA Gives Green Signal to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

May 20, 2022

Indaptus Therapeutics Inc. (NASDAQ: INDP) was up 19% after the US Food and Drug Administration cleared its Investigational New Drug Application for first phase clinical trial in advanced solid tumors patients where currently available therapies have failed. Trading Data On Thursday, INDP stock moved up 18.80% to $2.97 with 25.51 million shares, compared to its average volume of 452K shares. The stock moved within a range of $2.8000 – 3.1800…

Read More >>